Zimmer Biomet Net Worth
Zimmer Biomet Net Worth Breakdown | ZBH |
Zimmer Biomet Net Worth Analysis
Zimmer Biomet's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Zimmer Biomet's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Zimmer Biomet's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Zimmer Biomet's net worth analysis. One common approach is to calculate Zimmer Biomet's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Zimmer Biomet's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Zimmer Biomet's net worth. This approach calculates the present value of Zimmer Biomet's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Zimmer Biomet's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Zimmer Biomet's net worth. This involves comparing Zimmer Biomet's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Zimmer Biomet's net worth relative to its peers.
To determine if Zimmer Biomet is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zimmer Biomet's net worth research are outlined below:
| Zimmer Biomet has a strong financial position based on the latest SEC filings | |
| Over 94.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Zimmer Biomet wins CE Mark for RibFix Advantage |
Zimmer Biomet Quarterly Good Will |
|
Zimmer Biomet uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zimmer Biomet Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zimmer Biomet's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Zimmer Biomet Target Price Consensus
Zimmer target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Zimmer Biomet's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 30 | Buy |
Most Zimmer analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Zimmer stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Zimmer Biomet Holdings, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationZimmer Biomet Target Price Projection
Zimmer Biomet's current and average target prices are 112.50 and 124.50, respectively. The current price of Zimmer Biomet is the price at which Zimmer Biomet Holdings is currently trading. On the other hand, Zimmer Biomet's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Zimmer Biomet Market Quote on 2nd of April 2025
Target Price
Analyst Consensus On Zimmer Biomet Target Price
Know Zimmer Biomet's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zimmer Biomet is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zimmer Biomet Holdings backward and forwards among themselves. Zimmer Biomet's institutional investor refers to the entity that pools money to purchase Zimmer Biomet's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Allspring Global Investments Holdings, Llc | 2024-12-31 | 2.6 M | Citadel Advisors Llc | 2024-12-31 | 2.4 M | Northern Trust Corp | 2024-12-31 | 2.4 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 M | Norges Bank | 2024-12-31 | 2 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 2 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.8 M | Hotchkis & Wiley Capital Management Llc | 2024-12-31 | 1.7 M | Boston Partners Global Investors, Inc | 2024-12-31 | 1.6 M | Vanguard Group Inc | 2024-12-31 | 22.9 M | Dodge & Cox | 2024-12-31 | 19.1 M |
Follow Zimmer Biomet's market capitalization trends
The company currently falls under 'Large-Cap' category with a total capitalization of 22.37 B.Market Cap |
|
Project Zimmer Biomet's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.17 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.07 |
When accessing Zimmer Biomet's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Zimmer Biomet's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zimmer Biomet's profitability and make more informed investment decisions.
Evaluate Zimmer Biomet's management efficiency
Zimmer Biomet Holdings has Return on Asset of 0.0465 % which means that on every $100 spent on assets, it made $0.0465 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0725 %, implying that it generated $0.0725 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The Zimmer Biomet's current Return On Tangible Assets is estimated to increase to 0.17, while Return On Capital Employed is projected to decrease to 0.06. As of now, Zimmer Biomet's Asset Turnover is decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 61.43 | 64.50 | |
| Tangible Book Value Per Share | (5.28) | (5.55) | |
| Enterprise Value Over EBITDA | 12.05 | 17.34 | |
| Price Book Value Ratio | 1.72 | 1.63 | |
| Enterprise Value Multiple | 12.05 | 17.34 | |
| Price Fair Value | 1.72 | 1.63 | |
| Enterprise Value | 14.4 B | 12.8 B |
Zimmer Biomet's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Enterprise Value Revenue 3.6527 | Revenue | Quarterly Revenue Growth 0.043 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zimmer Biomet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zimmer Biomet Corporate Filings
F3 | 13th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 25th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 19th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Zimmer Biomet Earnings Estimation Breakdown
The calculation of Zimmer Biomet's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Zimmer Biomet is estimated to be 1.7712 with the future projection ranging from a low of 1.7134 to a high of 1.92. Please be aware that this consensus of annual earnings estimates for Zimmer Biomet Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
1.71 Lowest | Expected EPS | 1.92 Highest |
Zimmer Biomet Earnings Projection Consensus
Suppose the current estimates of Zimmer Biomet's value are higher than the current market price of the Zimmer Biomet stock. In this case, investors may conclude that Zimmer Biomet is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Zimmer Biomet's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 30 | 96.57% | 2.31 | 1.7712 | 4.43 |
Zimmer Biomet Earnings History
Earnings estimate consensus by Zimmer Biomet Holdings analysts from Wall Street is used by the market to judge Zimmer Biomet's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Zimmer Biomet's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Zimmer Biomet Quarterly Gross Profit |
|
Zimmer Biomet Earnings per Share Projection vs Actual
Actual Earning per Share of Zimmer Biomet refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Zimmer Biomet Holdings predict the company's earnings will be in the future. The higher the earnings per share of Zimmer Biomet, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Zimmer Biomet Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Zimmer Biomet, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Zimmer Biomet should always be considered in relation to other companies to make a more educated investment decision.Zimmer Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Zimmer Biomet's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | 2.2927 | 2.31 | 0.0173 | 0 | ||
2024-10-30 | 2024-09-30 | 1.74 | 1.74 | 0.0 | 0 | ||
2024-08-07 | 2024-06-30 | 1.99 | 2.01 | 0.02 | 1 | ||
2024-05-02 | 2024-03-31 | 1.87 | 1.94 | 0.07 | 3 | ||
2024-02-08 | 2023-12-31 | 2.15 | 2.2 | 0.05 | 2 | ||
2023-11-07 | 2023-09-30 | 1.6 | 1.65 | 0.05 | 3 | ||
2023-08-01 | 2023-06-30 | 1.81 | 1.82 | 0.01 | 0 | ||
2023-05-02 | 2023-03-31 | 1.64 | 1.89 | 0.25 | 15 | ||
2023-02-03 | 2022-12-31 | 1.83 | 1.88 | 0.05 | 2 | ||
2022-11-02 | 2022-09-30 | 1.56 | 1.58 | 0.02 | 1 | ||
2022-08-02 | 2022-06-30 | 1.65 | 1.82 | 0.17 | 10 | ||
2022-05-03 | 2022-03-31 | 1.41 | 1.61 | 0.2 | 14 | ||
2022-02-07 | 2021-12-31 | 1.98 | 1.95 | -0.03 | 1 | ||
2021-11-04 | 2021-09-30 | 1.76 | 1.81 | 0.05 | 2 | ||
2021-08-03 | 2021-06-30 | 1.87 | 1.9 | 0.03 | 1 | ||
2021-05-04 | 2021-03-31 | 1.53 | 1.71 | 0.18 | 11 | ||
2021-02-05 | 2020-12-31 | 2.06 | 2.11 | 0.05 | 2 | ||
2020-11-06 | 2020-09-30 | 1.07 | 1.81 | 0.74 | 69 | ||
2020-08-04 | 2020-06-30 | -0.73 | 0.05 | 0.78 | 106 | ||
2020-05-11 | 2020-03-31 | 1.38 | 1.7 | 0.32 | 23 | ||
2020-02-04 | 2019-12-31 | 2.27 | 2.3 | 0.03 | 1 | ||
2019-11-05 | 2019-09-30 | 1.75 | 1.77 | 0.02 | 1 | ||
2019-07-26 | 2019-06-30 | 1.91 | 1.93 | 0.02 | 1 | ||
2019-04-26 | 2019-03-31 | 1.86 | 1.87 | 0.01 | 0 | ||
2019-02-01 | 2018-12-31 | 2.17 | 2.18 | 0.01 | 0 | ||
2018-10-26 | 2018-09-30 | 1.6 | 1.63 | 0.03 | 1 | ||
2018-07-27 | 2018-06-30 | 1.88 | 1.92 | 0.04 | 2 | ||
2018-04-26 | 2018-03-31 | 1.89 | 1.91 | 0.02 | 1 | ||
2018-01-30 | 2017-12-31 | 2.1 | 2.1 | 0.0 | 0 | ||
2017-11-01 | 2017-09-30 | 1.74 | 1.72 | -0.02 | 1 | ||
2017-07-27 | 2017-06-30 | 2.1 | 2.08 | -0.02 | 0 | ||
2017-04-27 | 2017-03-31 | 2.11 | 2.13 | 0.02 | 0 | ||
2017-01-31 | 2016-12-31 | 2.11 | 2.14 | 0.03 | 1 | ||
2016-10-31 | 2016-09-30 | 1.79 | 1.79 | 0.0 | 0 | ||
2016-07-28 | 2016-06-30 | 1.97 | 2.02 | 0.05 | 2 | ||
2016-04-28 | 2016-03-31 | 1.93 | 2.0 | 0.07 | 3 | ||
2016-01-28 | 2015-12-31 | 2.04 | 2.09 | 0.05 | 2 | ||
2015-10-29 | 2015-09-30 | 1.56 | 1.64 | 0.08 | 5 | ||
2015-07-30 | 2015-06-30 | 1.55 | 1.59 | 0.04 | 2 | ||
2015-04-30 | 2015-03-31 | 1.51 | 1.58 | 0.07 | 4 | ||
2015-01-29 | 2014-12-31 | 1.7 | 1.71 | 0.01 | 0 | ||
2014-10-23 | 2014-09-30 | 1.3 | 1.35 | 0.05 | 3 | ||
2014-07-24 | 2014-06-30 | 1.49 | 1.49 | 0.0 | 0 | ||
2014-04-24 | 2014-03-31 | 1.47 | 1.5 | 0.03 | 2 | ||
2014-01-30 | 2013-12-31 | 1.62 | 1.66 | 0.04 | 2 | ||
2013-10-24 | 2013-09-30 | 1.24 | 1.25 | 0.01 | 0 | ||
2013-07-25 | 2013-06-30 | 1.44 | 1.43 | -0.01 | 0 | ||
2013-04-25 | 2013-03-31 | 1.4 | 1.41 | 0.01 | 0 | ||
2013-01-31 | 2012-12-31 | 1.49 | 1.51 | 0.02 | 1 | ||
2012-10-25 | 2012-09-30 | 1.13 | 1.15 | 0.02 | 1 | ||
2012-07-26 | 2012-06-30 | 1.32 | 1.34 | 0.02 | 1 | ||
2012-04-26 | 2012-03-31 | 1.3 | 1.3 | 0.0 | 0 | ||
2012-01-26 | 2011-12-31 | 1.34 | 1.36 | 0.02 | 1 | ||
2011-10-27 | 2011-09-30 | 1.03 | 1.04 | 0.01 | 0 | ||
2011-07-27 | 2011-06-30 | 1.19 | 1.21 | 0.02 | 1 | ||
2011-04-28 | 2011-03-31 | 1.12 | 1.19 | 0.07 | 6 | ||
2011-01-27 | 2010-12-31 | 1.19 | 1.27 | 0.08 | 6 | ||
2010-10-28 | 2010-09-30 | 0.95 | 0.96 | 0.01 | 1 | ||
2010-07-22 | 2010-06-30 | 1.05 | 1.09 | 0.04 | 3 | ||
2010-04-22 | 2010-03-31 | 1.01 | 1.02 | 0.01 | 0 | ||
2010-01-28 | 2009-12-31 | 1.08 | 1.12 | 0.04 | 3 | ||
2009-10-22 | 2009-09-30 | 0.86 | 0.88 | 0.02 | 2 | ||
2009-07-23 | 2009-06-30 | 0.96 | 1.0 | 0.04 | 4 | ||
2009-04-23 | 2009-03-31 | 0.94 | 0.95 | 0.01 | 1 | ||
2009-01-29 | 2008-12-31 | 1 | 1.0 | 0.0 | 0 | ||
2008-10-23 | 2008-09-30 | 0.89 | 0.97 | 0.08 | 8 | ||
2008-07-22 | 2008-06-30 | 1.03 | 1.03 | 0.0 | 0 | ||
2008-04-24 | 2008-03-31 | 1.04 | 1.04 | 0.0 | 0 | ||
2008-01-29 | 2007-12-31 | 1.04 | 1.18 | 0.14 | 13 | ||
2007-10-24 | 2007-09-30 | 0.91 | 0.91 | 0.0 | 0 | ||
2007-07-25 | 2007-06-30 | 0.98 | 0.98 | 0.0 | 0 | ||
2007-04-25 | 2007-03-31 | 0.93 | 0.98 | 0.05 | 5 | ||
2007-01-29 | 2006-12-31 | 0.99 | 1.02 | 0.03 | 3 | ||
2006-10-25 | 2006-09-30 | 0.75 | 0.77 | 0.02 | 2 | ||
2006-07-26 | 2006-06-30 | 0.82 | 0.83 | 0.01 | 1 | ||
2006-04-26 | 2006-03-31 | 0.81 | 0.82 | 0.01 | 1 | ||
2006-01-30 | 2005-12-31 | 0.83 | 0.86 | 0.03 | 3 | ||
2005-10-26 | 2005-09-30 | 0.67 | 0.7 | 0.03 | 4 | ||
2005-07-27 | 2005-06-30 | 0.75 | 0.8 | 0.05 | 6 | ||
2005-04-25 | 2005-03-31 | 0.67 | 0.75 | 0.08 | 11 | ||
2005-01-31 | 2004-12-31 | 0.64 | 0.71 | 0.07 | 10 | ||
2004-10-25 | 2004-09-30 | 0.53 | 0.56 | 0.03 | 5 | ||
2004-07-28 | 2004-06-30 | 0.55 | 0.58 | 0.03 | 5 | ||
2004-04-26 | 2004-03-31 | 0.51 | 0.56 | 0.05 | 9 | ||
2004-02-09 | 2003-12-31 | 0.48 | 0.51 | 0.03 | 6 | ||
2003-10-22 | 2003-09-30 | 0.41 | 0.43 | 0.02 | 4 | ||
2003-07-23 | 2003-06-30 | 0.42 | 0.45 | 0.03 | 7 | ||
2003-04-23 | 2003-03-31 | 0.38 | 0.41 | 0.03 | 7 | ||
2003-01-29 | 2002-12-31 | 0.34 | 0.37 | 0.03 | 8 | ||
2002-10-21 | 2002-09-30 | 0.3 | 0.33 | 0.03 | 10 | ||
2002-07-24 | 2002-06-30 | 0.3 | 0.34 | 0.04 | 13 | ||
2002-04-24 | 2002-03-31 | 0.25 | 0.28 | 0.03 | 12 | ||
2002-02-05 | 2001-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2001-10-30 | 2001-09-30 | 0.23 | 0.25 | 0.02 | 8 |
Zimmer Biomet Corporate Directors
| Arthur Higgins | Independent Director | Profile | |
| Michael Michelson | Independent Director | Profile | |
| Christopher Begley | Lead Independent Director | Profile | |
| Betsy Bernard | Independent Director | Profile |
Already Invested in Zimmer Biomet Holdings?
The danger of trading Zimmer Biomet Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zimmer Biomet is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zimmer Biomet. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zimmer Biomet Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.41) | Dividend Share 0.96 | Earnings Share 4.43 | Revenue Per Share | Quarterly Revenue Growth 0.043 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.